A

Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Real vaqt narxi. Valyuta: USD

12.60

-0.18 (-1.41%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Real vaqt narxi. Valyuta: USD

12.60

-0.18 (-1.41%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07.05.2026

Amneal Reports First Quarter 2026 Financial Results

‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒

29.04.2026

Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

29.04.2026

Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?

The consensus price target hints at a 34.8% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

29.04.2026

Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

29.04.2026

Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?

Here is how Alignment Healthcare (ALHC) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

29.04.2026

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Amneal Reports First Quarter 2026 Financial Results

‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒

22.04.2026

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This acquisition combines Kashiv's extensive expertise in the development and manufacturing o.

22.04.2026

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance – – Company to Host Investor Conference Call Today at 8:30 a.m. EST – BRIDGEWATER, N.J.

20.04.2026

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function after switching to CREXONT® Patients switching to CREXONT® from RYTARY® gained 3.07 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of effective symptom control BRIDGEWATER, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN).

Search stocks

Amneal Pharmaceuticals, Inc. (AMRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amneal Pharmaceuticals, Inc. (AMRX)

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Amneal Reports First Quarter 2026 Financial Results

Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?

Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?

Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Videolar

No Data

Press-relizlar

Amneal Reports First Quarter 2026 Financial Results

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®